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OBJECTIVES We investigated whether autoantibodies against the human beta-adrenergic receptor (beta-
AR) might be involved in cardiomyopathies secondary to valvular heart disease (VHD) or
hypertensive heart disease (HHD).
BACKGROUND Autoimmunity to beta-AR has been proposed as a pathogenic principle in human cardio-
myopathy. Recently, by the use of intact recombinant human beta-AR, we were able to
confirm the existence of functionally active anti-beta-1-AR autoantibodies in patients with
dilated cardiomyopathy (26% prevalence) or ischemic cardiomyopathy (10% prevalence);
however, their prevalence in other (secondary) cardiomyopathies remained to be determined.
METHODS Immunoglobulin G (IgG) was prepared from the sera of 28 VHD and 19 HHD patients and
first screened by a peptide-based enzyme-linked immunosorbent assay (antigens: aminoter-
minus, second extracellular loop [ECII] and carboxyterminus of human beta-1- and
beta-2-AR). IgG from 108 gender- and age-matched healthy subjects served to define the
threshold for positive immunoreactions. Positive sera were further screened for their ability to
recognize and activate native human beta-AR situated in a cell membrane.
RESULTS Twenty-five percent (VHD) or 11% (HHD) of the patients and 4% of the healthy controls
had IgG antibodies randomly directed against all the three domains tested and both beta-AR
subtypes. Only one patient with aortic valve and concomitant coronary heart disease and one
healthy subject had functionally active anti-b1-AR (targeting beta-1-ECII). Moreover, one
HHD patient with concomitant collagenosis had IgG that was cross-reacting with recom-
binant beta-AR in immunological assays but was unable to affect receptor function.
CONCLUSIONS Autoimmune reactions against the human beta-AR do not appear to be associated with
cardiomyopathies secondary to VHD or HHD. (J Am Coll Cardiol 1999;34:1545–51) ©
1999 by the American College of Cardiology
Since the first reports on the detection of stimulating
anti-beta-adrenergic receptor (anti-beta-AR) autoantibod-
ies in patients with Chagas cardiomyopathy (1), a growing
body of evidence suggests that autoimmunity to cardiac
beta-ARs might be associated with several other human
cardiomyopathies as well (2,3). Recently, we established a
screening strategy for detecting functionally relevant anti-
beta-AR in patients suffering from dilated cardiomyopathy
(DCM) or ischemic cardiomyopathy (ICM) by the use of
recombinant intact human beta-AR expressed in various cell
types (4). Previously generated subtype- and domain-
specific anti-beta-AR rabbit antibodies enabled us to define
positive immunoreactions (5). Confirming the results from
earlier studies (2,3), in both DCM and ICM we detected a
subset of patients with circulating immunoglobulin G (IgG)
antibodies able to recognize native human beta-1-AR in a
cell membrane and activate and/or sensitize these receptors
through a direct (allosteric) receptor-antibody interaction.
Their prevalence was 26% in DCM and 10% in ICM,
respectively, and was associated with a significant reduction
in cardiac function (4).
However, in other kinds of heart disease also accompa-
nied by reduced left ventricular function (and finally severe
heart failure), the prevalence and possible implication of
such activating anti-beta-1-AR remained to be evaluated.
Consequently, in the present study, we used the newly
established tools to screen the sera of 47 patients suffering
from cardiomyopathies secondary to valvular (valvular heart
disease [VHD], n 5 28) or hypertensive heart disease
([HHD], n 5 19) for functionally active autoantibodies
targeting the human beta-AR.
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METHODS
Patients and sample acquisition. Forty-seven patients
were recruited in the course of routine heart catheterization
and coronary angiography: 28 patients suffered from chronic
VHD (VHD subgroup; Table 1); 19 patients had a long-
lasting clinical history of hypertension (22 6 9 years) and
suffered from advanced states of HHD (HHD subgroup).
All patients had dyspnea corresponding to New York Heart
Association functional classes II to IV, a left ventricular
diastolic volume .110 ml/m2 and an ejection fraction
,55% (ventriculography). For HHD patients, significant
coronary heart disease could be excluded by angiography,
whereas three patients from the VHD subgroup had con-
comitant beginning (one-vessel disease, less than 50% ste-
nosis), and one VHD patient had severe coronary artery
disease but no prior infarction in clinical history. Because
this patient had significant aortic valve stenosis (accompa-
nied with severe aortic valve regurgitation) but no patho-
logical Q-waves in the electrocardiogram, he was assigned
to the VHD subgroup. At the time of sample acquisition, all
patients were stable under therapy with diuretics, angioten-
sin converting enzyme inhibitors, digitalis or nitrates; five
patients also received amlodipine. None was treated with
beta-receptor blockers or beta-receptor agonists. One
hundred eight healthy blood donors matched for gender
(female/male 5 38/70) and age (48 6 18 years) served as
controls (collective identical to our previous study [4]).
Table 2 summarizes the basic clinical and hemodynamic
data of the patient subgroups analyzed.
IgG was prepared from the sera by caprylic acid precip-
itation; the concentration was determined by immune-
nephelometry (BN-II; Dade-Behring, Marburg, Germany),
and for the assays, all samples were normalized to 1,000 mg
IgG/ml.
Immunoassays with synthetic antigens. For enzyme-
linked immunosorbent assay (ELISA), synthetic peptides
corresponding to the second extracellular loop of the human
beta-1- or beta-2-AR were synthesized commercially (ami-
Abbreviations and Acronyms
anti-beta-1-AR/-ECII 5 antibodies against the beta-1-
adrenergic receptor/second
extracellular loop of the beta-
1-adrenergic receptor
beta-AR 5 beta-adrenergic receptor
BSA 5 bovine serum albumin
DCM 5 dilated cardiomyopathy
ELISA 5 enzyme-linked
immunoabsorbent assay
HHD 5 hypertensive heart disease
HPLC 5 high-performance liquid
chromatography
ICM 5 ischemic cardiomyopathy
IgG 5 immunoglobulin G
PBS 5 phosphate-buffered saline
VHD 5 valvular heart disease
Table 1. Characteristics of the Patients With Chronic Valve Disease
Degree of Leading
Valve Dysfunction
Aortic Valve Disease
(n 5 21) (F/M: 9/12)
Mitral Valve Disease
(n 5 7) (F/M: 3/4)
AS AR MS MR
Mild to moderate
AS, VOA ,0.8 cm2/m2 Bsa
MS, VOA ,1.5 cm2/m2 Bsa 6 (3*) 5 1 2
AR/MR severity grade I–II
Severe
AS, VOA ,0.4 cm2/m2 Bsa
MS, VOA ,0.8 cm2/m2 Bsa 6 (1*) 4 1 3
AR/MR severity grade III
*Number of patients with concomitant sclerosis of the coronary arteries.
AR 5 aortic valve regurgitation; AS 5 aortic valve stenosis; Bsa 5 body surface area; F 5 female; M 5 male; MR 5 mitral
valve regurgitation; MS 5 mitral valve stenosis; VOA 5 valve opening area (calculated by the Gorlin equation after cardiac
catheterization).
Table 2. Clinical and Hemodynamic Parameters of Patient
Subgroups With Valvular or Hypertensive Heart Disease
Parameter
VHD
(n 5 28)
HHD
(n 5 19)
Age (yrs) 63 6 7 55 6 12
Gender (F/M) 12/16 9/10
NYHA state 2.8 6 0.2 2.2 6 0.5
Heart rate (per min) 81 6 3 78 6 3
PVR (dynzszcm25) 151 6 88 138 6 47
SVR (dynzszcm25) 1433 6 424 1635 6 389
EFangio (%) 44.9 6 3.2 47.6 6 4.9
CI (lzmin21zm22) 2.66 6 0.3 2.91 6 0.4
Cont. (mm Hgzs21) 1249 6 90 1536 6 151
Relax. (mm Hgzs21) 990 6 55 1295 6 104
Data are mean values 6 SEM.
Cont. 5 contractility (peak dP/dt), and Relax. 5 relaxation (peak negative dP/dt),
both derived from left ventricular high fidelity time/pressure curves. CI 5 cardiac
index; EFangio 5 left ventricular ejection fraction (ventriculography); HHD 5
hypertensive heart disease; PVR 5 pulmonary vascular resistance; SVR 5 systemic
vascular resistance; VHD 5 valvular heart disease.
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no acids 195 to 225 or 169 to 200, according to the amino
acid sequences of the human beta-1- [6] or beta-2-AR [7],
respectively). Amino- and carboxy-terminal fusion proteins
of both receptor subtypes were produced in Escherichia coli
as described previously (5), and fragments corresponding to
the respective receptor-domains were isolated by high-
performance liquid chromatography (HPLC) after throm-
bin digestion of the fusion products (to cleave off the
bacterial fusion partner). Peptide (5 ng/well) or protein were
coated onto 96-well microtiter plates (Maxisorb; Nunc,
Kastrup, Denmark), incubated with two different IgG
concentrations (25 and 12.5 mg/ml, each in triplicate) for
12 h at 4°C and washed six times before the addition of
biotinylated secondary rabbit anti-human IgG antibodies
(1:5,000), streptavidin-peroxidase and o-phenylenediamine
(Sigma, Deisenhofen, Germany). Optical densities were
read at 490 nm.
Dot-blots were obtained using the same antigens as
above, spotted onto activated nitrocellulose membranes (8)
(Hybond C; Amersham, Buckinghamshire, UK). In addi-
tion to the selected receptor fragments, in this assay the IgG
fractions were also checked against spots of bovine serum
albumin (BSA) and a nonreceptor control peptide. The
membranes were probed with 50 mg/ml of the human IgG
preparations for 2 h at 37°C, washed eight times and after
incubation with horseradish peroxidase-conjugated goat
anti-human IgG secondary antibodies, immunoreactive
dots were visualized by enhanced chemiluminescence
(ECL; Amersham).
Immunoassays with intact recombinant receptors.
Whole cell lysates or intact unfixed Sf9 insect cells infected
with recombined baculovirus AcMNPV-beta-1-AR or
-beta-2-AR transiently expressing 1 to 2 3 106 human
beta-1- or beta-2-AR (4,9) were utilized for native Western
blotting and immunofluorescence studies. Wild-type virus-
infected Sf9 cells served as negative controls. Presence of the
receptor antigens was checked with previously characterized
subtype-specific rabbit anti-beta-AR (positive control) (5).
Sf9 cell lysates were subjected to native Western blotting as
previously described (4,10) and incubated with 50 mg/ml of
the patient IgG for 12 h at 4°C. Immunoreactive bands were
visualized by enhanced chemiluminescence (see above).
Immunofluorescence experiments were performed on in-
tact unfixed Sf9 cells, suspended in phosphate-buffered
saline (PBS) containing 2 mmol/liter MgCl2 and 2% BSA.
The cells were incubated with human IgG fractions (167
and 83 mg/ml) for 6 h at 4°C and then washed three times
before the addition of CY3-labeled anti-human IgG sec-
ondary antibodies (Dianova, Hamburg, Germany) to detect
receptor-bound patient IgGs. Fluorescence of the cells was
inspected by a fluorescence microscope (400-fold magnifi-
cation; Zeiss-Axioplan, Jena, Germany) and photographed
with identical exposure times.
Assays on receptor-mediated cAMP accumulation. The
cAMP assay was carried out on stably transfected Chinese
hamster fibroblasts expressing 100 to 120 fmol/mg human
beta-1-AR (CHW-beta-1 cells) (4). Cellular cAMP was
determined by 125I-labeled cAMP scintillation proximity
assay (Biotrak Kit; Amersham) in three independent exper-
iments. In brief, confluent cells were preincubated with
40 mg IgG/ml from patients and healthy controls for 1 h at
37°C in the presence of 0.5 mmol/liter isobutylmethylxan-
thine. Subsequently, the cells were either stimulated with
10 mmol/liter (2)isoproterenol or not, and incubation
continued for 15 min at 37°C. After washing the cells two
times with medium, cytoplasmic cAMP was extracted with
boiling water, and the supernatants were directly used for
the scintillation assay.
Statistical analysis. The threshold for a significantly in-
creased reactivity in ELISA was based on the statistical
distribution of n 5 108 gender- and age-matched healthy
control subjects (mean 6 2 SD). Statistical analysis of the
cAMP assay was done by two-factorial ANOVA, using the
experimental condition and the disease entity as factors
(F 5 2,032 [basal vs. stimulated] and F 5 13.8 [intergroup
differences], respectively; p , 0.001). Subgroup analysis was
done by Scheffe´’s F-test (post hoc multiple comparison
procedure). The observed power (beta-1) of the method was
superior to 99.9% (functional assay). Recently, by using the
same approach, we were able to detect n 5 17/65 DCM and
n 5 4/39 ICM patients who had: 1) IgG antibodies
activating cellular cAMP production and 2) significantly
reduced cardiac function (Cardiac index 2.21 6 0.1 vs.
2.81 6 0.1 liters/min/m2; p , 0.001 [4]).
RESULTS
Screening with synthetic beta-adrenergic receptor pep-
tides. Sera of patients suffering from VHD or HHD and
healthy controls were initially screened for IgG antibodies
capable of binding to synthetic peptides corresponding to
the aminoterminus, second extracellular loop, or carboxy-
terminus of human beta-1- and beta-2-AR, as previously
described (4). An increased reactivity in ELISA was as-
sumed for signals above the upper limit of the respective
95% confidence intervals (mean 6 2 SD) of the healthy
subjects. By this criterion, 36% of the patient IgG (39% of
the VHD and 32% of the HHD subgroup) revealed
increased reactivity with at least one of the selected receptor
domains (Fig. 1, left). Fifty-nine percent of the positive sera
showed either multiple reactivity with different receptor
domains (Fig. 1, numbers in parentheses) or cross-reactions
between the beta-1- and beta-2-receptor subtype (Fig. 1,
hatched bars). This high prevalence of multiple reactivity
indicated either a polyclonal immune response against the
whole receptor molecule or high levels of nonspecific bind-
ing.
In order to select IgG antibodies specifically binding to
the above synthetic receptor fragments, all IgG fractions
with increased reactivity in ELISA were further checked for
nonspecific binding to BSA and to a nonreceptor control
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peptide by dot-blotting (not shown). The number of pa-
tients still remaining antibody-positive indicated that more
than half of the multiple reactions with several receptor
domains were obviously due to nonspecific binding: 25%
(n 5 7/28) and 11% (n 5 2/19) of the VHD and HHD
patients, respectively, and less than 4% of the healthy
subjects (n 5 4/108), had circulating antibodies specific for
synthetic beta-AR domains. These immunoreactive IgGs
were directed with similar frequency against all three do-
mains tested and both beta-AR subtypes.
Immunofluorescence-studies on native human beta-
adrenergic receptors. Immunoreactive IgG specifically
binding to synthetic receptor fragments was further checked
for their capability of recognizing intact native human
beta-AR. Only two of the patient IgG preparations (one
from either subgroup) stained the membranes of Sf9 cells
bearing beta-AR in their native conformation. These IgG
antibodies were the ones directed against the second extra-
cellular loop of the beta-1-AR subtype (anti-b1-ECII).
However, none of the antibodies was able to recognize the
receptors on renatured Western blots of Sf9 cell lysates,
suggesting that anti-b1-ECII preferentially recognize a
specific native receptor conformation that is sensitive to
denaturation and cannot be completely restored after West-
ern blotting. Figure 2 shows the typical membrane staining
pattern of Sf9 cells transiently expressing human beta-1-
(top) or beta-2-AR (middle) upon incubation with subtype-
specific anti-beta-AR rabbit antibodies (Fig. 2, rabbit anti-
b1/2) (5). Wild-type virus-infected Sf9 cells not expressing
beta-AR served as a negative control (bottom). Because
these control cells were clearly (nonspecifically) stained by
the immunoreactive IgG from the HHD patient, the
membrane fluorescence pattern seen with beta-AR-
expressing Sf9 cells was presumably not receptor-specific
(Fig. 2, HHD). Interestingly, further clinical examination of
this patient revealed concomitant systemic lupus erythema-
tosus accompanied with a high titer of antinuclear antibod-
ies (ANA titer 1:3,200) but no anticardiolipin antibodies. In
a singular instance, the IgG antibodies of one of the VHD
patients, which according to ELISA and dot-blotting were
directed against the beta-1-ECII peptide (but also revealed
cross-reactivity with beta-1-N; see Fig. 1, VHD, right),
gave a fluorescence pattern similar to that obtained with
anti-beta-1-AR rabbit antibodies (Fig. 2). These IgGs had
been isolated from a patient with moderate to severe
Figure 1. Screening of patients with VHD or HHD, or healthy
controls (Healthy) for anti-beta-AR autoantibodies. (Left) In-
creased reactivity in ELISA with synthetic peptides corresponding
to the aminoterminal (N), second extracellular (ECII), or carboxy-
terminal (C) domains of human beta-1- (open bars), or beta-2-
(closed bars), or both receptor subtypes (hatched bars). (Right)
Sera specifically recognizing receptor peptides selected for binding
(IFM 5 indirect fluorescence microscopy, see Fig. 2) and func-
tional interaction (increase in cAMP, see Fig. 3) with intact
human beta-AR. Bars represent the number of positive results for
each epitope; numbers in parentheses (on top of the bars) indicate
cross-reactions with another receptor domain. The total number of
autoantibody-positive individuals is given underneath each dia-
gram (brackets).
Figure 2. Detection of anti-beta-AR antibodies by immunofluo-
rescence microscopy. Intact native Sf9 cells expressing recombi-
nant human beta-AR (b1/b2), or infected with wild-type vector
(W) were probed with subtype-specific anti-beta-AR rabbit anti-
bodies (5) (Rabbit, anti-b1/b2), with IgG from an antibody-
negative healthy subject (Healthy), or with IgG from a patient
with chronic valvular and concomitant ischemic heart disease
recognizing only the beta-1-AR (VHD), or a patient with hyper-
tensive heart disease and concomitant collagenosis recognizing
both beta-AR bearing Sf9 cells and wild-type virus-infected
control cells (nonspecific staining, HHD).
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combined aortic valve disease. However, left heart catheter-
ization and coronary angiography revealed that this patient
at the same time suffered from significant stenosis of the
proximal left descendant anterior artery and of the proximal
portion of the left circumflex artery. The ventriculogram
showed diffuse reduction in wall motion, suggesting con-
comitant ischemic cardiomyopathy (left ventricular ejection
fraction 15%; cardiac index 1.7 liters/min/m2).
None of the IgG preparations from healthy subjects who
were not reacting with synthetic receptor peptides in
ELISA (Fig. 2, Healthy), or from patients and controls
recognizing only the amino- and/or carboxyterminal recep-
tor domains, stained native beta-AR expressed in Sf9 cells.
However, 1 out of 108 healthy control subjects could be
identified who had antibodies that recognized both the
beta-1-ECII peptide and the native intact beta-1-AR ex-
pressed in Sf9 cells (Fig. 1, Healthy, right). At the time of
sample acquisition, this individual had no cardiac abnormal-
ities (as assessed by echocardiography and electrocardio-
gram) and no pathological findings in the routine blood
chemistry, including a screening for antinuclear antibodies.
Antibody effects on receptor-mediated cellular signaling.
All immunoreactive IgG fractions were also tested for
possible functional effects by the use of stably transfected
CHW-b1 cells. Only the IgG antibodies from the
fluorescence-positive VHD patient and those from the only
positive healthy control subject (able to recognize and to
bind to native human beta-1-AR) affected receptor-
mediated signaling (Fig. 3). In the presence of these
antibodies, basal cAMP levels were significantly increased
by 1.48 6 0.08- (VHD patient) or 1.19 6 0.09-fold
(Healthy positive), and isoproterenol-stimulated cAMP
production was also increased by 1.39 6 0.14- or 1.09 6
0.04-fold, respectively (Fig. 3b). These data confirm our
previous findings, that functionally relevant human anti-
beta-1-AR may enhance receptor-mediated cAMP accu-
mulation (4). By contrast, the IgG preparations from all the
other healthy controls (n 5 15) and patients (n 5 17)
analyzed in the frame of the present study, including those
of the HHD patient nonspecifically staining the membranes
of beta-AR expressing Sf9 cells, had no effect on basal or
agonist-stimulated cAMP production in repeated experi-
ments (Fig. 3, Healthy negatives and HHD patient).
DISCUSSION
The second extracellular loop of the beta-1-AR as
autoantigen. Since the first reports on circulating anti-
beta-AR autoantibodies in cardiomyopathy, several groups
have investigated the possible role and functional implica-
tion of receptor-directed autoimmune reactions in the
development and/or course of human heart disease (2,3).
However, depending on the respective screening strategies
and immunological detection methods employed, the re-
ports on the prevalence and/or functional impact of such
receptor antibodies differed to some extent (2,3,11). Re-
cently, by using the molecular tools developed during the
past few years (5–7,9), we were able to confirm the existence
of functionally active human anti-beta-1-AR in a subgroup
of patients suffering from DCM or ICM (4). Similar to
those from the antibody-positive (VHD) patient in the
present study, all of these antibodies were directed against
the fairly small second extracellular loop domain of the
human beta-1-AR (anti-beta-1-ECII), which is in agree-
ment with previous findings from a Swedish group (2).
Although this loop is probably not directly involved in
receptor-ligand binding (12), because of its disulfide-
bonded cysteines, it might be important for the correct
folding of the receptor molecule: 1) for ligand accessibility
(13) or 2) for transition into an active receptor state (as
demonstrated for the beta-2-AR [14]). In addition, this
loop has been shown to contain epitopes capable of stimu-
lating immunoreactive B- and T-cells in vivo (15), which
could explain its possible role as autoantigen.
The positive staining of beta-1-AR in native cells and the
negative results of Western blots suggest that anti-b1-ECII
antibodies preferentially bind to the receptor in its native
conformation. Thereby, they appear to be able to increase
both basal and isoproterenol-stimulated intracellular second
messenger (cAMP) levels. Such functionally active anti-
beta-1-AR antibodies might act by promoting an active
receptor conformation and, thus, sensitize the beta-
adrenergic system for catecholamines, which in a failing
heart could further potentiate the vitious circle of adren-
ergic overdrive (16). In agreement with this hypothesis, the
only activating antibody-positive (VHD) patient identified
Figure 3. cAMP-levels of CHW-beta-1 cells upon incubation
with different patient IgG preparations. The cells were stimulated
with 10 mmol/liter (2) isoproterenol (hatched bars) or not (black
bars) either (a: left) (error bars: 6 SD) in the absence (Controls)
or presence of IgG fractions from antibody-negative control
subjects (Healthy, negatives), or (b: right) (error bars: 6 SD of
three independent experiments) after preincubation with
immunofluorescence-positive IgG fractions from an HHD patient
also staining Sf9 control cells (left), a VHD patient with concom-
itant ICM (middle) and the only positive control subject (right).
Significant differences compared with antibody-negative healthy
individuals are denoted by (*)p , 0.1, *p , 0.05 and **p , 0.001
(Scheffe´’s F-test, post-hoc multiple comparison).
1549JACC Vol. 34, No. 5, 1999 Jahns et al.
November 1, 1999:1545–51 Beta-receptor Antibodies in Cardiomyopathy
here suffered from severe cardiac dysfunction (cardiac index
1.7 liters/min/m2), and in our previous study on patients
with DCM and ICM, the prevalence of activating anti-
beta-1-AR was also strongly associated with a more reduced
left ventricular function (4). Thus, it can be imagined that
autoantibody-mediated activation of beta-1-AR might
have adverse effects on the clinical course of a certain
subset of human cardiomyopathies, similarly to a number
of other receptor-targeted autoimmune diseases in which
autoantibodies have been shown to influence the progres-
sion of disease (17).
Receptor-antibodies in valvular and HHD. The results
from our study indicate that activating anti-beta-AR auto-
antibodies are unlikely to play a major role in cardiomyop-
athies secondary to VHD or HHD, which would be in
agreement with recent findings from other groups suggest-
ing an association of primary hypertension with autoanti-
bodies directed against alpha-1-adrenergic rather than beta-
adrenergic receptors (18,19). First, the immunoreactive
(IgG) antibodies from the VHD and HHD collectives
(determined by ELISA and dot-blotting) were randomly
directed with a similar frequency against all the three
domains tested and both beta-AR subtypes. This is in clear
contrast to our previous results obtained for a DCM
collective with a high prevalence of functionally relevant
anti-beta-AR (34% antibody-positive sera, 83% directed
against the second extracellular receptor domain with a 86%
recognition of the beta-1-AR [4]). Second, of all the VHD
and HHD patients with IgG antibodies able to interact
with synthetic receptor fragments, only one (VHD) patient
remained who according to the previously defined criteria
(4) had circulating, functionally active anti-beta-1-AR
(again targeting beta-1-ECII). Third, because this VHD
patient at the same time suffered from significant coronary
heart disease, it seems likely that the autoantibodies have to
be ascribed to concomitant ICM rather than to VHD. In
addition, the functional effects obtained with this IgG
preparation were similar to those previously reported for a
subgroup of receptor autoantibody-positive patients with
DCM or ICM (4), thus confirming the existence of func-
tionally relevant anti-beta-1-AR in these two subsets of
human cardiac disease. In addition, we identified one
healthy subject who also had activating anti-beta-1-AR
antibodies. We have not yet had the opportunity to follow
this individual long term to determine whether he develops
cardiomyopathy, nor do we have any data that would
support an implication of genetic factors in the occurrence
of functionally active autoantibodies. As a consequence, we
intend a long-term follow-up of all receptor autoantibody-
positive individuals so far identified to investigate whether
activating anti-beta-AR might represent a suitable marker
for the development and/or progression of DCM and/or
ICM. Another interesting finding from this study was that
one HHD patient suffering from a well-defined systemic
autoimmune disorder (systemic lupus erythematosus) had
circulating polyspecific IgG antibodies, which were also able
to cross-react with intact native human beta-AR (immuno-
fluorescence); however, these antibodies had no effect on
receptor-mediated signaling (Fig. 3b, HHD).
Summary and perspective. Taken together, in a minor
fraction of the sera from patients with cardiomyopathies
secondary to VHD or HHD, we found IgG antibodies
reacting with synthetic beta-AR peptides in ELISA. This
finding is partially in agreement with previous reports from
other groups (3,18,20). However, with one exception, none
of these antibodies was able to specifically bind to intact
native human beta-AR, and none of them affected receptor-
mediated signaling. Thus, an approach solely based on
ELISA seems not to be suited for detecting functionally
relevant anti-beta-AR antibodies in patients (4,11). By
applying more stringent screening criteria and, in particular,
the use of functionally coupled recombinant human
beta-AR situated in a cell membrane, the patient subgroups
analyzed here showed no significant extent of anti-beta-AR
autoantibodies. This indicates that autoimmune reactions
directed against the beta-AR are unlikely to be associated
with cardiomyopathies secondary to VHD or HHD.
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